Renca-Luc

Renca-Luc is a bioluminescent derivative of the murine Renca renal carcinoma cell line, engineered to stably express a firefly luciferase reporter gene. The parental Renca cell line was spontaneously derived from a renal cell carcinoma in a BALB/c mouse and is one of the most widely used syngeneic models for renal cell carcinoma (RCC) in immuno-oncology research. Renca tumors grow aggressively and are poorly immunogenic in BALB/c hosts, making this model valuable for evaluating immunotherapy approaches including checkpoint inhibitors, cytokine therapies, and cancer vaccines in an immunocompetent setting that recapitulates the immunosuppressive microenvironment characteristic of human RCC.

The stable luciferase integration in Renca-Luc enables sensitive, noninvasive bioluminescence imaging (BLI) of tumor burden in orthotopic subrenal capsule and subcutaneous xenograft models in syngeneic BALB/c mice. Following luciferin administration, the emitted signal correlates with viable tumor cell number, supporting longitudinal monitoring of tumor engraftment, growth kinetics, and therapeutic response without repeated invasive procedures. Renca-Luc is widely used for in vivo evaluation of anti-RCC agents, combination immunotherapy strategies, and angiogenesis inhibitors in preclinical renal cancer research.

Renca-Luc retains the established biological and immunological properties of the parental Renca line, including BALB/c syngeneic compatibility and its characteristic poorly immunogenic phenotype. The luciferase modification substantially enhances experimental sensitivity and enables real-time pharmacodynamic assessment of treatment efficacy. Researchers should verify luciferase activity, growth kinetics, and immunological characteristics under their specific experimental conditions prior to large-scale in vivo use.